Samsung biosimilar on its way


The European regulator has approved the first biosimilar referencing etanercept*, making it the second biosimilar anti-TNF to reach the market. The biosimilar marketed as Benepali is made by Samsung Bioepis, a joint venture between Samsung Biologics and Biogen. The company holds a commercialization partnership with MSD. It has been approved in Europe  for the treatment ...


Already a member? Login to keep reading


OR
© 2017 the limbic